- Home
- CRMD vs JQC Comparison
CRMD vs JQC Comparison
Compare CRMD & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRMD | JQC |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.0M | 706.6M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRMD | JQC |
|---|---|---|
| Price | $8.79 | $4.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.83 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 589.0K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.13% |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.38 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $6.13 | $4.62 |
| 52 Week High | $17.43 | $5.58 |
Technical Indicators
Market Signals| Indicator | CRMD | JQC |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 45.49 |
| Support Level | $8.09 | $4.76 |
| Resistance Level | $9.01 | $4.88 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 70.34 | 18.75 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.